Weekly low dose methotrexate is an established treatment for rheumatoid art
hritis, but its use in elderly people has not been adequately examined. The
aim of this study was to evaluate its safety in elderly patients with rheu
matoid arthritis. A retrospective review of the clinical records of rheumat
oid arthritis patients over the age of 65 attending a rheumatology unit was
conducted. Eligible patients were followed for at least two years and trea
ted with methotrexate in a dose of 7.5 mg/week while being maintained on co
ncurrent treatment. Thirty three patients were studied. Their mean age was
78.8 years; 32 were female and one was male. Treatment was discontinued in
four patients, two because of raised serum liver enzymes and two because of
gastrointestinal irritation. No serious adverse events were reported. Afte
r two years, haemoglobin levels increased from a mean (SD) of 12.4 (1.3) g/
dl to 13.0 (1.1) g/dl (r = 0.226, p < 0.005). The white blood count was sig
nificantly reduced from 7.9 (1.8) x 10(9)/1 to 6.8 (1.7) x 10(9)/1 (r = 0.1
84, p < 0.05). No episodes of neutropenia or agranulocytosis were observed.
There was a nonsignificant decrease in platelet count. The erythrocyte sed
imentation rate decreased from 56.8 (30.8) to 35.2 (24.6) mm/h (r 0.246, p
< 0.01). In conclusion, low methotrexate treatment in elderly patients appe
ars to be safe. Routine determination of serum liver enzymes and renal func
tion may reduce individual risk.